Core Viewpoint - Huiyu Pharmaceutical (688553.SH) expects a net loss attributable to shareholders of the parent company for the fiscal year 2025, ranging from a loss of 29 million yuan to a loss of 24 million yuan, representing a year-on-year decline of 108.91% to 107.38% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 78 million yuan and 93 million yuan for 2025, which indicates a year-on-year change of a decline of 15.33% to an increase of 0.96% compared to the previous year [1] Investment Impact - The company's invested enterprise, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., is set to be listed on the Hong Kong Stock Exchange under the 18A listing standard on August 20, 2024, with the stock code 02410.HK [1] - The fair value change loss of 173 million yuan during the reporting period was influenced by the stock price fluctuations of the invested enterprise [1]

格隆汇1月28日｜中国证监会国际合作司发布关于浙江同源康医药股份有限公司境内未上市股份"全流 通"备案通知书，公司1名股东拟将所持合计4,608,000股境内未上市股份转为境外上市股份，并在香港联 合交易所上市流通。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） H股全流通尚須履行聯交所及其他境內外監管機構所要求的其他相關程序。本公 司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 內幕消息 中國證監會發出關於本公司申請H股全流通的備案通知書 本公告乃由浙江同源康醫藥股份有限公司（「本公司」）根據香港聯合交易所有限公 司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證 券及期貨條例第XIVA部項下內幕消息條文（「內幕消息條文」）（定義見上市規則） 作出。 茲提述本公司日期為2025年6月6日的公告（「該公告」），內容有關本公司向中國證 監會申請（「中國證監會備案」）H股全流通。除文義另有所指外，本公告所用詞彙 與該公告所界定者具有相同涵義。 董事會欣然宣佈，近日中國證監會已就H股全流通向本公司發出備案 ...

Core Viewpoint - The company has received a Drug Manufacturing License from the Zhejiang Provincial Drug Administration, which is expected to positively impact its capacity expansion and market development in the long term [1] Group 1: License Acquisition - The company has been granted a Drug Manufacturing License, which lays the foundation for future commercial production [1] - This license is anticipated to enable the company to provide better treatment options for patients, addressing urgent medical needs in cancer treatment [1] Group 2: Market Impact - The acquisition of the license is expected to have a long-term positive effect on the company's ability to expand its production capacity and market reach [1]

智通财经APP讯，同源康医药-B(02410)公布，公司获浙江省药品监督管理局颁发的《药品生产许可 证》。本次获得药品生产许可证，预期将对公司扩大产能及拓展市场产生长远的积极作用，为后续开展 商业化生产奠定基础，有望早日为患者提供更好的治疗选择，以满足癌症治疗中亟待满足的医疗需求。 ...

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410.HK) has received a Drug Manufacturing License from the Zhejiang Provincial Drug Administration, which is expected to positively impact the company's capacity expansion and market development in the long term [1]. Group 1: License Details - The company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., is registered at 1278 Mingzhu Road, Changxing Economic Development Zone, Huzhou, Zhejiang Province [1]. - The production address is entrusted to Kailaiying Life Science Technology (Tianjin) Co., Ltd., located at No. 71, Seventh Avenue, Tianjin Economic Development Zone [1]. - The license number is Zhe20260002, valid until January 22, 2031, issued by the Zhejiang Provincial Drug Administration [1]. Group 2: Implications of the License - The acquisition of the Drug Manufacturing License is anticipated to lay the foundation for the company to commence commercial production [1]. - This development is expected to provide better treatment options for patients, addressing urgent medical needs in cancer treatment [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410) 自願公告 本公司獲浙江省藥品監督管理局頒發《藥品生產許可證》 浙江同源康醫藥股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願刊 發，以告知本公司股東及潛在投資者有關本集團最新業務發展的資料。 I. 藥品生產許可證主要信息 企業名稱：浙江同源康醫藥股份有限公司 註冊地址：浙江省湖州市長興縣長興經濟開發區明珠路1278號長興世貿大廈 A座14層1403-2室 生產地址和生產範圍：受託生產企業：凱萊英生命科學技術（天津）有限公 司，天津開發區第七大街71號，甲磺酸艾多替尼片*** 許可證編號：浙20260002 有效期至：2031年1月22日 簽發機關：浙江省藥品監督管理局 1 II. 對本公司的影響 本次獲得藥品生產許可證，預期將對本公司擴大產能及拓展市場產生長遠的 ...

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 4%, currently trading at 14.21 HKD with a transaction volume of 59.4 million HKD, following the announcement of its new drug's inclusion in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1 - The company is developing a first-class new drug, Tysun (TY-9591), which targets adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have specific EGFR mutations and CNS metastasis [1] - The NMPA's decision to include TY-9591 in the priority review list is a significant milestone for the company, potentially expediting the drug's approval process [1] - The intended indication for TY-9591 is for first-line treatment in patients with EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations [1]

Group 1 - The company, 同源康医药-B, announced that its investigational drug,甲磺酸艾多替尼片 (TY-9591), is proposed to be included in the priority review list by the National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with specific EGFR mutations [3] - The board of directors noted unusual fluctuations in the company's stock price and trading volume but confirmed that, apart from the disclosed information, they are not aware of any reasons for these fluctuations or any material information that needs to be disclosed to avoid misleading the market [3] - As of the date of the announcement, the board confirmed that the company's business operations are stable and progressing smoothly, with no significant matters requiring disclosure that would raise concerns for the board or management [3]

Core Viewpoint - The company, ZhiYuanKang Pharmaceutical-B (02410), announced that its investigational drug, TY-9591 (Axitinib), is proposed to be included in the priority review list by the National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1] Group 1 - The proposed indication for TY-9591 is for adult patients with NSCLC who have either exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, along with central nervous system (CNS) metastases [1] - The company's board has noted unusual fluctuations in the stock price and trading volume, but confirmed that they are not aware of any reasons for these fluctuations beyond what has been disclosed [1] - As of the date of the announcement, the board confirmed that the company's business operations are stable and progressing smoothly, with no significant matters requiring disclosure [1]